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ABSTRACT
Duloxetine, milnacipran, and pregabalin are
approved by the United States Food and Drug
Administration for the management of
fibromyalgia. A number of meta-analyses,
pooled analyses, and systematic reviews have
been published in recent years involving the
efficacy of these three medications for pain in
fibromyalgia. Despite being based on the same
clinical data, some analyses found these
treatments to have a clinically relevant effect on
pain, while others concluded that the advantages
were small or of questionable clinical relevance.
This commentary discussed possible reasons
behind these differing conclusions and explored
ways of evaluating the clinical relevance of
pharmacological treatments for fibromyalgia. In
particular, we considered: (1) the importance of
judicious and careful interpretation of average
treatment effect size and the recognition that
average treatment effect sizes do not always tell
the whole story; (2) the utility of individual
patient response data to assess clinical relevance;
and (3) the importance of considering pain
reduction within the context of other benefits
due to the presence of associated symptoms in
patients with fibromyalgia.
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INTRODUCTION
Fibromyalgia (FM) is a common chronic pain
condition with multiple associated symptom
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domains. While FM is diagnosed based on the
presence of chronic pain and tenderness [1],
patients also frequently experience other
symptoms, including fatigue, poor sleep,
anxiety, and depression [2]. Three
medications (duloxetine [3], milnacipran [4],
and pregabalin [5]) have been approved by the
United States Food and Drug Administration
(FDA) for the management of FM. Several well-
controlled, high-quality clinical trials have
demonstrated the efficacy of these treatments
for the management of FM [6–18]. A number
of meta-analyses, pooled analyses, and
systematic reviews of pharmacological
interventions for FM have been published in
recent years [19–35]. However, these analyses
have not always reached the same conclusions
regarding the clinical meaningfulness of trial
results, despite often involving data from the
same studies. This is likely due, in part, to
differences in how a clinically meaningful
result was defined, as there is no definitive
definition of what constitutes a clinically
relevant or meaningful improvement in
symptoms in FM.
In this commentary, we highlight some key
points we believe should be considered when
determining the clinical relevance of
pharmacological treatments for FM: (1) the
importance of judicious and careful
interpretation of average treatment effect size
and the recognition that average treatment
effect sizes do not always tell the whole story;
(2) the utility of individual patient response
data to assess clinical relevance; and (3) the
importance of considering pain reduction
within the context of other benefits due to the
presence of associated symptoms in patients
with FM.
USE OF AVERAGE TREATMENT
EFFECT SIZE TO DETERMINE
CLINICAL RELEVANCE
Average treatment effect sizes have been used
by several meta-analyses and systematic reviews
[19, 23, 27, 32, 34] to evaluate the efficacy of
interventions for FM based on thresholds
defined by Cohen, which categorize effect sizes
as small [standardized mean difference (SMD) of
0.2], medium (SMD of 0.5), and large (SMD of
0.8) [36] (SMD is the difference in means
between active and control groups divided by
their pooled standard deviation). Among these
is a recent analysis by Nuesch et al. [19], the
most comprehensive meta-analysis of
pharmacological and non-pharmacological
interventions for FM published to date.
Nuesch et al. concluded that current evidence
best supports the use of serotonin-
norepinephrine reuptake inhibitors (SNRIs;
specifically, duloxetine or milnacipran) or
pregabalin in combination with non-
pharmacological therapies as treatment for
FM, an approach supported by recent
guidelines and recommendations for FM
management [37–39]. However, regarding the
efficacy of individual interventions for FM,
Nuesch et al. [19] remarked that the ‘‘benefits
for SNRIs and pregabalin compared with
placebo were statistically significant but small
and not clinically relevant’’.
While the observed effect sizes of FM
medications were not large according to
Cohen’s classification [36], we question
whether use of these categories as a stand-
alone gauge of clinical meaningfulness is
appropriate, since they are based solely on
statistical distributions and not on clinical
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criteria per se. Categorization of effect sizes can
help to summarize the signal-to-noise
magnitude of therapeutic effects; however, we
believe more can be done to assess fully the
therapeutic benefit to patients. Many approved
treatments are expected to have average effect
sizes in the small-to-moderate range, which
explains why larger sample sizes are needed in
clinical trials, but that is not to say that
treatment effects are not clinically significant.
It is important to consider, for example, that
average treatment effect sizes do not fully
characterize the spectrum of treatment
responses observed in chronic pain patients. It
is also worthwhile to distinguish between
responders and non-responders by evaluating
individual patient data, based on predefined
thresholds that are relevant to the condition
[20, 29, 40, 41].
IMMPACT RECOMMENDATIONS
AND USE OF PATIENT RESPONSE
THRESHOLDS TO DETERMINE
CLINICAL RELEVANCE
The initiative on methods, measurement, and
pain assessment in clinical trials (IMMPACT) has
recommended classifying pain responses in
chronic pain patients as minimally important
(10–20% pain reduction from baseline),
moderately important (C30%), and substantial
(C50%), based on three chronic pain studies that
assessed changes in pain scores (on a numerical
rating scale from 0 to 10) along with patient
impressions of overall improvement [42]. A
threshold of 30% change from baseline in the
Brief Pain Inventory average pain and severity
scores has been confirmed in a recent study as a
minimally clinically relevant response in an FM
population [43]. Responder analysis is a useful
way to complement and supplement an analysis
based on means, and has been recommended by
regulatory bodies as a way to establish clinically
relevant benefits [44, 45]. Responder analysis
can also be extended to show the cumulative
proportion of responders and of all patients over
a range of possible cutoff points [44, 46, 47],
further enhancing the interpretation of patient
responses.
Several meta-analyses and pooled analyses of
clinical trials of the FDA-approved FM
medications have used the IMMPACT C30%
threshold to define a clinically relevant
response [20, 24–26, 29, 30, 33–35]. These
analyses have estimated response rates (C30%
improvement in pain score) of up to 49% for
60–120 mg/day duloxetine (compared with up
to 32% for placebo) [26, 33, 35], up to 61% for
100–200 mg/day milnacipran (compared with
up to 36% for placebo) [20, 24], and up to 43%
for 150–450 mg/day pregabalin (compared with
up to 29% for placebo) [25, 29, 30, 34]. These
data indicate that a substantial proportion of
patients experience a clinically meaningful
response to active treatment of pain associated
with FM. Even after accounting for a placebo
effect, differences in responder rates between
active and placebo treatments are noteworthy.
ADDITIONAL BENEFITS
Patients with FM identify several symptoms in
addition to chronic pain that have a negative
impact on their quality of life, including sleep
disturbance, fatigue, depression, anxiety, and
cognitive impairment [48]. A recent analysis of
FM responder definitions suggested that
inclusion of assessments of symptom and
functional domains in addition to pain could
significantly improve the ability of clinical trials
to identify clinically meaningful improvements
[49]. In addition, improvements in fatigue,
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physical function, and sleep, as well as pain,
have individually been shown to correlate well
with improvements on the patient global
impression of change scale [24, 49–51], which
provides an indication of overall patient
improvement.
Duloxetine, milnacipran, and pregabalin have
been shown to have positive effects not only on
pain but also on secondary symptom domains of
FM [27]. Specifically, duloxetine was shown to be
effective for sleep disturbance, depressed mood,
and health-related quality of life (HR-QoL);
milnacipran for fatigue, depressed mood, and
HR-QoL; and pregabalin for fatigue, sleep
disturbance, and HR-QoL. Pregabalin-mediated
pain relief has also been shown to reduce the
number of work days lost by FM patients by more
than 1 day per week [52]. We suggest that all
potential effects of an intervention, benefits, and
harms, should be considered when evaluating
the net clinical benefit, particularly for a
condition such as FM. This assessment should
also take into account the potential for adverse
events, contraindications, and patient comorbid
conditions. The most common adverse reactions
to these medications (occurring in at least 5% of
treated patients and at least twice the incidence
of placebo patients) are nausea, dry mouth,
somnolence, constipation, decreased appetite,
and hyperhidrosis for duloxetine [3]; nausea,
headache, constipation, dizziness, insomnia,
hot flush, hyperhidrosis, vomiting, palpitations,
increased heart rate, dry mouth, and
hypertension for milnacipran [4]; and dizziness,
somnolence, dry mouth, edema, blurred vision,
weight gain, and abnormal thinking (primarily
difficulty with concentration or attention) for
pregabalin [5]. All three medications were
generally well tolerated in clinical trials of
patients with FM, with the majority of patients
successfully completing the trials [3–5].
CONCLUSIONS AND FUTURE
PERSPECTIVES
It is important for clinicians and patients with
FM to have a realistic idea of the potential net
clinical benefit of pharmacological FM
treatments. Clinical trials and meta-analyses of
FM treatments should evaluate not only the
statistical significance of a study outcome, but
also its clinical significance. Studies should
attempt to clearly define, when possible, a
clinically important change for key measures
at their outset, and examine patient-level
responses in addition to average treatment
effects in order to enhance the clinical
interpretation of treatment benefit. The fact
that standards and practices in evidence-based
health care depend on conversion from the
research to clinical setting should not be
underestimated. Finally, it is important to
consider the benefits of treatments for FM
beyond their effect on pain, taking into
account their effects on other related
comorbidities and symptoms, and overall
patient function and quality of life.
This commentary has focused on
pharmacological interventions for FM; however,
several studies have showed the positive effects of
non-pharmacological interventions, including
exercise [53], hydrotherapy [54], and cognitive-
behavioral therapy [55]. Multi-modal treatment,
including at least one educational treatment and
one exercise therapy, has also been shown to
have short-term benefits [56]. While it may not
be feasible for trials of non-pharmacological
therapies to achieve the same high
methodological and regulatory standards as
trials of pharmacological therapies (for instance,
in exercise trials it is not possible to blind
participants to their treatment), we believe that
the points raised in this commentary could be
68 Pain Ther (2013) 2:65–71
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also worthy of consideration for trials of non-
pharmacological interventions.
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